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Abstract
Introduction: There is no consensus on how to investigate men with negative transrectal ultrasound guided prostate
biopsy (TRUS-B) but ongoing suspicion of cancer. Three strategies used are transperineal (TP-B), transrectal saturation (TS-B)
and MRI-guided biopsy (MRI-B). We compared cancer yields of these strategies.
Methods: Papers were identified by search of Pubmed, Embase and Ovid Medline. Included studies investigated biopsy
diagnostic yield in men with at least one negative TRUS-B and ongoing suspicion of prostate cancer. Data including age,
PSA, number of previous biopsy episodes, number of cores at re-biopsy, cancer yield, and Gleason score of detected cancers
were extracted. Meta-regression analyses were used to analyse the data.
Results: Forty-six studies were included; 12 of TS-B, 14 of TP-B, and 20 of MRI-B, representing 4,657 patients. Mean patient
age, PSA and number of previous biopsy episodes were similar between the strategies. The mean number of biopsy cores
obtained by TP-B and TS-B were greater than MRI-B. Cancer detection rates were 30?0%, 36?8%, and 37?6% for TS-B, TP-B,
and MRI-B respectively. Meta-regression analysis showed that MRI-B had significantly higher cancer detection than TS-B.
There were no significant differences however between MRI-B and TP-B, or TP-B and TS-B. In a sensitivity analysis
incorporating number of previous biopsy episodes (36 studies) the difference between MRI-B and TP-B was not maintained
resulting in no significant difference in cancer detection between the groups. There were no significant differences in
median Gleason scores detected comparing the three strategies.
Conclusions: In the re-biopsy setting, it is unclear which strategy offers the highest cancer detection rate. MRI-B may
potentially detect more prostate cancers than other modalities and can achieve this with fewer biopsy cores. However,
well–designed prospective studies with standardised outcome measures are needed to accurately compare modalities and
define an optimum re-biopsy approach.
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Introduction
Prostate cancer is the most common male cancer [1]. The vast
majority of cancers are diagnosed from a transrectal ultrasound
guided biopsy of the prostate (TRUS-B) following the finding of a
raised PSA or abnormal digital rectal examination. The diagnostic
yield of a first transrectal ultrasound guided biopsy is commonly
40–50% [2]. This represents a significantly high detection rate
from a primary diagnostic intervention. It is however known that
first-line prostate biopsy protocols such as traditional TRUS-B,
even when used as an extended biopsy protocol of 12 cores will
miss about 30% of prostate cancers [3]. Cancer detection rates in
repeat TRUS-B range from 18% [4] to 32% [5]. Cancer will still
be detected after multiple repeat TRUS-Bs, though the cancer
detection rate falls with each repeat biopsy episode [6]. Even so the
standard TRUS-B only allows limited access to the prostate and
from the same anatomical approach, typically resulting in
undersampling of the prostatic apex and anterior region of the
gland [7].
A number of different techniques for prostate re-biopsy have
been developed and tested in an attempt to improve cancer
detection rates following an initial negative biopsy. These include
saturation biopsy approaches (either transperineal or transrectal)
or image guided (typically Magnetic Resonance Imaging) biopsies.
In the initial biopsy setting it has been shown that the use of
saturation biopsy techniques, which obtain greater number of
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prostate cores, either by transrectal or transperineal routes have no
advantage over standard TRUS-B with respect to cancer detection
rate [8,9]. In the repeat biopsy setting however, it is known that
the use of saturation biopsy detects more cancer than TRUS-B
alone [3,10]. MRI is well established as the staging modality of
choice for prostate cancer; particularly in the assessment of
extracapsular extension [11] but the use of MRI guided prostate
biopsy (MRI-B) for diagnosis is still relatively new. A number of
different techniques have been described for both the imaging of
the prostate and the approach used to obtain the biopsy specimen.
The use of T1 and T2-weighted MRI, [12] diffusion weighted
MRI (MRI-DW), [13] MR spectroscopy (MRSI), [14] dynamic
contrast enhanced MRI (DCE-MRI), [15] and various combina-
tions of the above in multi-parametric imaging protocols [16–18]
have all been described for the identification of prostatic lesions for
targeted biopsy. The biopsy specimen can then be obtained by
using transrectal, [12] transperineal, [19] or transgluteal ap-
proaches [20]. In the initial biopsy setting MRI guided biopsies
have been shown to have a cancer detection rate of 54% [21]. A
recent systematic review has reported that although requiring
fewer cores MRI guided biopsies had similar initial detection rates
compared to standard TRUS-B [22]. Thus in the initial biopsy
setting neither transperineal, transrectal saturation biopsy, or
image guidance have been shown to increase the yield of cancers
nor indeed improve detection of clinically significant tumours
[8,9,22].
What remains unclear from the existing literature is which
repeat biopsy strategy offers the highest cancer detection rate in
patients with a negative TRUS-B but ongoing suspicion of
prostate cancer [23]. This group is arguably the one most in need
of an optimal and unified strategy and where there is a justifiable
need for resource intensive alternative to standard TRUS-B. In
this study, we asked what the comparative cancer detection rates
were between the three repeat biopsy strategies of transperineal
biopsy (TP-B), transrectal saturation biopsy (TS-B), and MRI
guided biopsy (MRI-B).
Methods
Search Criteria
A literature search of Pubmed, Embase and Ovid Medline
databases was performed using the search terms ‘prostate’ and
‘biopsy’. Results were limited to the English language published
since 1st January 1995 and up to January 2012. Three re-biopsy
strategies were compared in this study: TP-B; multiple needle core
prostate biopsy obtained through the perineum with or without
the use of a brachytherapy grid template under transrectal
ultrasound (TRUS) guidance; TS-B; multiple needle core prostate
biopsy obtained transrectally under TRUS guidance and MRI-B;
multiple needle core prostate biopsy obtained after the use of MRI
to identify areas of the prostate suspicious for the presence of
cancer. We did not distinguish between the various functional
imaging modalities or biopsy approaches used in MRI-B for
simplicity of analysis due to the diversity of techniques described in
the current literature. The inclusion criteria for this study were
papers investigating biopsy diagnostic yield in men who had one or
more previous negative TRUS-B, who were undergoing one of the
three repeat biopsy strategies outlined above for ongoing suspicion
of prostate cancer, defined as elevated or rising PSA, abnormal
digital rectal examination (DRE) of the prostate and/or previous
high grade prostatic intraepithelial neoplasia (HGPIN) or atypical
small acinar proliferation (ASAP) on previous prostate biopsy.
Studies of men with known prostate cancer were excluded. In
papers where both initial and repeat biopsies were being studied,
only data relating to patients undergoing the repeat biopsy
procedure were analysed.
Data Analysis
The following data were extracted from each paper: first author,
year of publication, study size, mean patient age, mean PSA at
repeat biopsy, mean number of previous biopsy episodes, mean
number of biopsy cores taken at repeat biopsy, cancer detection
rate, and Gleason scores of detected cancers. Statistical analysis
was performed by RCH and RAP. For each strategy, weighted
summary statistics, which weight according to the sample size of
each individual study, were calculated for mean patient age, mean
PSA, mean number of previous biopsy episodes, and mean
number of cores obtained by the repeat biopsy strategy. We were
not able to weight by the inverse study variance for these variables
because estimates of within-study variability were unavailable. For
the primary outcome (cancer detection rate) however an estimate
of the variance could be extracted using the formula for the
variance of a proportion, and so this variable was weighted by the
inverse variances. A meta-regression analysis compared the overall
prostate cancer detection rate (percentage of patients diagnosed
with prostate cancer) between the three re-biopsy strategies having
adjusted for differences in mean patient age and PSA between the
strategy cohorts. In order to account for heterogeneity between
studies, a random-effects meta-regression analysis was conducted
using inverse-variance weights. The amount of residual heteroge-
neity between studies was assessed using a Q-test, based on the
DerSimonian-Laird estimator. Publication bias was assessed using
a funnel plot of the inverse sample variance against model
residuals (Figure 1) and a rank correlation test for funnel plot
asymmetry performed [24]. A sensitivity analysis was then
performed to see if adjusting for the number of previous biopsy
episodes affected the meta-regression results. Finally, to compare
average pathological outcomes across the repeat biopsy strategies,
a Fisher’s Exact test was applied to test for any association between
average tumour grade and re-biopsy strategy. The ‘metafor’
package [25] in R software [26] was used to perform the meta-
regression analysis. R software was also used to produce the
bubble plot and perform the Fisher’s Exact test for the Gleason
score analysis. SPSS software was used for all other analyses
(SPSS/PASW for Windows, Rel. 18.0.3. 2010. Chicago: SPSS
Inc.).
Results
Data Analysed
The literature search yielded 1,943 papers, which were then
individually screened for this study. 1,884 papers were excluded, as
they did not meet the inclusion criteria. Forty-nine papers met the
inclusion criteria for this study, however three of these were
subsequently excluded. In two of these papers data on mean age
and mean PSA was not available, [27,28] and in one paper using
both transperineal and transrectal biopsy approaches the cancer
detection rates with respect to each approach were not reported
separately [29]. Therefore, the necessary data for analysis could
not be extracted from the published report. A final 46 papers were
included in this analysis comprising 14 studies of TP-B, [23,30–42]
12 studies of TS-B, [30,43–53] and 20 studies of MRI-B [12–
18,20,54–65] (Figure 2, PRISMA flow diagram Figure S1,
PRISMA checklist Figure S2). The total number of patients
included in these papers was 4,657. A funnel plot of the model
residuals against standard error showed no clear evidence of
publication bias (Figure 1) and the rank correlation test of residuals
against sampling variance produced a low Kendall’s tau correla-
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tion coefficient of 0?06 (p= 0?56), demonstrating no clear evidence
of publication bias.
Baseline characteristics of the studies analysed are shown in
Table 1. The cohort size of each study and the cancer detection
rates for the three re-biopsy strategies are represented as a bubble
plot in Figure 3. Overall the TS-B approach had the largest
population sizes while MRI-B studies tended to include the
smallest numbers of patients. Of the 20 MRI-B studies analysed,
18 obtained prostate biopsies by the transrectal route, one by the
transperineal route, and one by the transgluteal route. Four studies
used T1 and T2 weighted MRI, seven used T1 and T2 weighted
MRI with MRSI, four used T1 and T2 weighted MRI with DCE-
MRI, one used T1 and T2 weighted MRI with MRI-DW, two
used T1 and T2 weighted MRI, MRSI and DCE-MRI, and two
used T1 and T2 weighted MRI, MRSI, DCE-MRI and MRI-
DW.
Weighted Summary Statistics
The weighted summary values for mean patient age, mean PSA
at the time of re-biopsy, mean number of previous biopsy episodes,
and mean number of prostate cores obtained at re-biopsy for each
strategy are displayed in Table 2. As data relating to within-study
variability was unavailable, formal statistical comparison of the
summary values was not possible. However, it can be seen that
patient mean age, mean PSA and mean number of previous
biopsy episodes are similar between the three re-biopsy strategies.
Cancer detection rates were estimated to be 28?4% (95% CI 22?0
to 34?7%), 37?1% (95% CI 31?7 to 42?5%), and 37?2% (95% CI
30?9 to 43?4%) for TS-B, TP-B and MRI-B respectively. After
taking into account the study variances, the cancer detection rates
were calculated to be 30?0%, 36?8%, and 37?6% for TS-B, TP-B
and MRI-B respectively. The mean number of cores obtained by
TP-B and TS-B was greater than MRI-B.
Meta-regression Analysis of Cancer Detection Rates
Forty-six studies comprising 14 TP-B, 12 TS-B, and 20 MRI-B
papers were analysed. In the meta-regression analysis MRI-B had
a significantly higher cancer detection rate than TS-B (8?55%,
95% CI 0?94 to 16?17, p = 0?03) (Table 3). However, there was no
statistically significant difference in the cancer detection rate
between TP-B and TS-B (7?91%, 95% 20?44 to 16?26, p = 0?06)
or between MRI-B and TP-B (0?64%, 95% CI 26?97 to 8?25,
p = 0?87). Mean age and PSA at re-biopsy were not significant
covariates in this model. Thus following adjustment for mean age
and PSA, the strategy used was the only variable which
significantly affected the cancer detection rate. After accounting
for differences due to strategy, mean age and mean PSA in the
meta-regression analysis, the amount of residual heterogeneity
between studies was calculated to be 76.0, which is highly
significant at the 5% level (QE=176.8, p,0.0001).
A sensitivity analysis was next performed, adjusting for the
mean number of biopsy episodes prior to the re-biopsy strategy
(Table 4). Ten studies were excluded from this analysis due to
missing data. Thus a total of 36 studies were eligible for use in this
Figure 1. Funnel plot showing a measure of variability (the standard error) of the cancer detection rate against the residuals from
the meta-regression model with results shown in Table 3 (main results table). The points represent different studies. Studies are distributed
evenly either side of the zero line suggesting no clear evidence of publication bias.
doi:10.1371/journal.pone.0057480.g001
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sub-analysis (11 TP-B, [23,30–32,34,36–39,41,42] nine TS-B,
[30,43–46,48–50,53] and 16 MRI-B papers [13–18,55–58,60–
65]). Again the test for residual heterogeneity was highly
significant (QE=142.7, p,0.0001). Here however we were no
longer able to identify any significant difference between the three
strategies (TP-B versus TS-B p= 0?12, MRI-B versus TS-B
p= 0?16, MRI-B versus TP-B p= 0?74) (Table 4). The most likely
reason for this was the reduced statistical power resulting from the
smaller sample size, because after re-fitting the original model to
the subset of 36 studies, the results were also non-significant (TP-B
versus TS-B 6?29%, 95% CI 23?57 to 16?15, p = 0?21); MRI-B
versus TS-B 5?98%, 95% CI 23?13 to 15?10, p= 0?20; MRI-B
versus TP-B, 20?31%, 95% CI 29?29 to 8?67, p= 0?95).
Analysis of Pathological Grades
Twenty-eight studies (61%) had median Gleason score available
for this analysis. Comparison of median Gleason scores by Fisher’s
exact test did not reveal any significant differences between the
strategies (p = 0?90). As only 28 studies had complete data
available for analysis of Gleason score we interpret these results
with caution. Nevertheless, we were unable to find any evidence of
a difference in the reported clinical significance (as defined by
Gleason sum) of the detected cancers between strategies.
Discussion
In this study we addressed the question of which repeat biopsy
strategy is most effective at diagnosing prostate cancer in men with
initial negative TRUS-B and ongoing suspicion of prostate cancer.
There is currently no published consensus on which re-biopsy
approach should be used in this group of men and the decision as
to which strategy to use is largely based on institutional practice
and the availability of a particular technology. A key observation
was the large heterogeneity across the studies included in the
analysis with regards the patient demographics, biopsies taken,
previous biopsy episodes, and outcome reporting. Our conclusions
were therefore based on analyses following correction for these
variables as much as possible. In the initial meta-regression
analysis our results demonstrated that MRI-B detected signifi-
cantly more cancer than TS-B, but there were no significant
differences between either MRI-B and TP-B, or TP-B and TS-B.
In a subset analysis correcting for number of prior biopsy episodes
however, this difference was not maintained. This was almost
certainly due to a loss of statistical power resulting from the
reduced number of studies available for inclusion in the sensitivity
analysis as when the 36 studies from the sensitivity analysis were
re-analysed using the initial meta-regression model, there were no
significant differences between the three re-biopsy strategies.
Additionally, the weighted summary statistics (Table 2) demon-
strated a similar mean number of previous biopsy episodes
between the three strategies, therefore it is unlikely that the
inclusion of this variable would influence the meta-regression
results. However, our analysis was not able to conclusively
demonstrate a clear benefit of one approach over another in
cancer detection rates. These results therefore suggest that at
present no one re-biopsy method can be recommended based
solely on current evidence available from the literature.
In this study TP-B and MRI-B had very similar cancer
detection rates but the latter achieved this with fewer biopsy
cores. It could therefore be said that MRI-B offers higher cancer
yield per biopsy core than the other strategies. These results are
consistent with the recent systematic analysis by Moore [22]
although that study did not differentiate between initial and re-
biopsy patients. It was not possible to formally compare
complication rates between the three re-biopsy strategies as part
of this analysis due to a lack of reported data in many studies.
Previous studies have not found a correlation between number of
cores and complication rates [66] and so further research is
needed to establish the complications associated with each of the
re-biopsy strategies analysed here.
It is well recognised that many detected cancers will be indolent
and not require active intervention [67]. The ideal biopsy strategy
Figure 2. Literature search results (TP-B- Transperineal biopsy, TS-B-Transrectal saturation biopsy, MRI-B – MRI guided biopsy).
doi:10.1371/journal.pone.0057480.g002
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therefore would achieve the maximal detection of clinically
significant cancers with fewest biopsy cores. In this regard MRI-
B may have the advantage as it alone allows a guided biopsy based
on a priori radiological knowledge of the prostate architecture and
morphology [22]. MRI-B however does require significantly
greater multidisciplinary input in its planning and execution as
well as access to good quality imaging and reporting. This may not
be available in all centres though the use of functional MRI in
routine clinical practice is expanding [68]. Certainly our data
would suggest that the cancer yield of TP-B does not significantly
differ from MRI-B, and would therefore be a reasonable
alternative to MRI-B.
The use of MRI for targeted prostate biopsy is a rapidly
evolving field and recent data suggests an improving ability to
better detect clinically significant cancers after initial negative
investigation [22,69,70]. In this analysis we were only able to assess
for differences in Gleason sum score between the groups and
found no significant difference in median scores. Clinical
significance of a tumour however may also be derived from other
variables such as the extent of core involvement and number of
cores involved. At the present time, there is no consensus on how
best to perform MRI-B in terms of both the approach to the
prostate and the choice of imaging modality [22,71]. The majority
of MRI-B studies in this analysis used the transrectal route to
obtain prostate biopsies with two studies using the transperineal
Figure 3. Bubble plot showing the cancer detection rates and respective size of each study in the three strategies. The size of the
bubble corresponds to the number of patients included (chart guide on the right of the figure). TP-B- Transperineal biopsy, TS-B-Transrectal
saturation biopsy, MRI-B – MRI guided biopsy.
doi:10.1371/journal.pone.0057480.g003
Table 2. Weighted summary statistics of data extracted from each paper by repeat biopsy strategy.
Strategy (no. studies) [no. patients] TP-B (14) [1756] TS-B (12) [1987] MRI-B (20) [914] Overall (46) [4,657]
Mean Age (years) 64?9 63?8 64?0 64?3
Mean PSA (ng/L) 11?0 9?0 10?6 10?1
Mean No. previous biopsy episodes{ 1?5 1?8 1?9 1?7
Mean No. Cores at repeat biopsy 30?4 24?0 9?8 24?8
Cancer Detection Rate (%) 36?8 30?0 37?6 34?0
{For the studies that do not report the mean number of biopsies, the median was used instead where possible. (TP-B – Transperineal biopsy, TS – B, Transrectal
saturation biopsy, MRI-B – MRI guided biopsy).
doi:10.1371/journal.pone.0057480.t002
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[59] or transgluteal [20] approach. The use of MRI/transrectal
ultrasound fusion to obtain targeted biopsies is also undergoing
investigation [59,64]. In a recent report of 49 patients undergoing
repeat biopsy Hadaschik [59] detected cancer in 45% of men
using MRI guided transperineal biopsy. Whilst this result is of
interest, the sample size is small and there is therefore a need for
further comparative evaluation of transperineal MRI-B, to see
whether cancer detection in the re-biopsy setting could be further
increased by fusion technology. It is clear that imaging guided
biopsies will continue to evolve and be focused on detecting
clinically significant cancers. Given the likely increased clinical
resource needs for MRI-B there is a clear rationale for well
designed prospective studies to compare the outcomes of different
biopsy approaches. This ideally should be in a randomised setting
and, if not feasible, then by robust prospective databases
incorporating standardised data collection as well as clinical and
pathological outcomes reporting. A forthcoming UK Health
Technology Assessment report due to be published this year, on
the diagnostic accuracy and cost-effectiveness of MRI techniques
in prostate biopsy may provide further information in this area.
Assessment of the diagnostic efficacy of any re-biopsy strategy
should, ideally be based on correlation of the biopsy findings with
step-sectioned radical prostatectomy specimens.
This study has a number of inherent limitations. Data was
extracted from published manuscripts, rather than from original
patient data, so a degree of reporting bias is inevitable. We have
acknowledged that there is heterogeneity of data across the studies
analysed despite efforts to standardise the data included in the
meta-regression analysis. We were unable to formally compare the
weighted summary statistics with statistical methodology as data
relating to within-study variability was not available from the
published manuscripts. We did not differentiate between the
various techniques of MRI-B, and so our findings with respect to
this strategy may not be applicable to each of the individual
techniques described in the literature. Finally, this study was not
able to accurately assess and compare the complication rates or
costs of each modality as these factors were often not well recorded
in the papers reviewed. An evaluation of these aspects in a
prospective study will be crucial in determining the health
economic cost benefits of each modality.
Conclusions
This study has compared the cancer detection rates of three re-
biopsy strategies in men with initial negative biopsies and ongoing
suspicion of prostate cancer. The main meta-regression analysis
demonstrated that MRI-B had a significantly higher cancer
detection rate than TS-B, but this result was not maintained after
adjustment for the mean number of prior biopsy episodes. Notably
MRI-B required the fewest biopsy cores to achieve the greatest
cancer detection rate. We observed considerable heterogeneity in
the studies in the literature. There is an urgent need for
prospective national and international audit and a common
reporting format to improve the quality of data for accurate
comparison of biopsy strategies and to investigate the complication
rates associated with each strategy. Quality of life and health
economic analyses should also be incorporated to better inform
clinical decision on the most efficient and cost effective re-biopsy
strategy.
Table 3. Meta-regression analysis with cancer detection rate of each strategy as the primary outcome.
Unstandardised
Coefficients
95% Confidence Interval.
Lower bound
95% Confidence
Interval. Upper bound P-value
Variables TS-B (Reference)
TP-B 7?91 20?44 16?26 0?063
MRI-B 8?55 0?94 16?17 0?028
Mean Age 0?46 21?55 2?47 0?653
Mean PSA 20?13 20?96 0?70 0?764
TS-B is shown as the reference category for the purpose of comparison with the other two strategies. (TP-B – Transperineal biopsy, TS-B – Transrectal saturation biopsy,
MRI-B – MRI guided biopsy).
doi:10.1371/journal.pone.0057480.t003
Table 4. Meta-regression analysis with cancer detection rate of each strategy as the primary outcome, adjusting for mean age,
mean PSA, and mean number of previous biopsies.
Unstandardised
Coefficients
95% Confidence
Interval. Lower bound
95% Confidence Interval.
Upper bound P-value
Variables TS-B (Reference)
TP-B 7?99 22?04 18?02 0?118
MRI-B 6?47 22?63 15?57 0?164
Mean Age 0?36 22?03 2?75 0?768
Mean PSA 20?36 21?55 0?84 0?558
Mean number of previous
biopsies
5?23 21?00 11?45 0?100
TS-B is shown as the reference category for the purpose of comparison with the other two strategies. (TP-B – Transperineal biopsy, TS-B –Transrectal saturation biopsy,
MRI-B – MRI guided biopsy).
doi:10.1371/journal.pone.0057480.t004
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